

***International Workshop on Viruses, Genes and Hematological Cancers,
in conjunction with the 15th European LeukemiaNet Symposium
March 19-22, 2018***

***Istituto Veneto di Scienze, Lettere ed Arti, Palazzo Cavalli Franchetti,
Campo Santo Stefano, Venezia, Italia***

Monday, March 19

13:45-14:45 Registration

14:45-15:20 Opening remarks

15:20-17:20 - **Session 1 – Viruses and leukemia/lymphoma.** Chairpersons: **Anita De Rossi** (University of Padova/IOV, Italy) and **Giuseppe Opocher** (University of Padova/IOV, Italy)

20' - **Charles R.M. Bangham** (Imperial College, London, UK): *'Regulation of latency in the human leukaemia virus HTLV-1'*

20' - **Roberto S. Accolla** (University of Insubria, Varese, Italy) *'Oncoproteins of Human T cell leukemia/Lymphoma Virus-1 (HTLV-1) and their involvement in HTLV-1-associated diseases'*

20' - **Anne Van den Broeke** (Jules Bordet Institute, ULB, Brussels/GIGA, Uliège, Liège, Belgium) *'HTLV-1/BLV genomics: towards a better understanding of leukemia progression'*

20' - **Silvia Giunco** (IOV, Padova, Italy) *'EBV-driven lymphomagenesis: cross-talk between EBV and telomerase'*

20' - **Giovanna Tosato** (National Cancer Institute, NIH, Bethesda, U.S.A.) *'Evidence for a mesothelial origin of primary effusion lymphoma'*

20' - **Ute Fischer** (Heinrich-Heine-University, Düsseldorf, Germany) *'Infection as a cause of childhood leukemia?'*

17:20-17:40 *Coffee break*

17:40-18:20

Keynote Lecture – Robert Gallo (Institute of Human Virology, Baltimore, U.S.A.)

'Nightmares of an Aging Viral Oncologist'

Introduction by Luigi Chieco-Bianchi (University of Padova, Italy)

18:45-19:45

Visit to the exhibition "il mondo che non c'era" – the Ligabue Collection of pre-Colombian art.

Palazzo Loredan

Tuesday, March 20

9:00-10:20 **Session 2 – Immunology and microenvironment.** Chairpersons: **Genoveffa Franchini** (National Cancer Institute, NIH, Bethesda, U.S.A.) and **Guido Poli** (San Raffaele Scientific Institute, Milan, Italy)

20' - **Genoveffa Franchini** (National Cancer Institute, NIH, Bethesda, U.S.A.) *'Trained Immunity in protection against HIV'*

20' - **Anna Aldovini** (Harvard Medical School, Boston, U.S.A.) *'Impact of in vivo p38 MAPK inhibition on SIV-mediated immune activation'*

20' - **Maurizio Zanetti** (University of California San Diego, La Jolla, U.S.A.) *'Cell nonautonomous ER stress in the tumor microenvironment'*

20' - **Antonio Rosato** (University of Padova/IOV, Italy) *'Antigen-specific redirection of Cytokine-Induced Killer (CIK) cells as a valuable alternative to CAR-T therapy'*

10:20-10:50 Coffee break

10:50-12:30 **Session 3 – Genetics and epigenetics.** Chairpersons: **Federico Caligaris-Cappio** (AIRC, Milan, Italy) and **Alberto Amadori** (University of Padova/IOV, Italy)

20' - **Jürgen Ruland** (Technische Universität, München, Germany) *'Antigen Receptor and Co-Receptor Signaling Pathways in Lymphoma: The Dark Side'*

20' - **Riccardo Dalla-Favera** (Columbia University, New York, U.S.A.) *'New Pathogenetic and Therapeutic Insights in Diffuse Large B Cell Lymphoma'*

20' - **Pier Giuseppe Pelicci** (Milan University/EIO, Milan, Italy) *'Regulation of cancer stem cell functions by environmental signals'*

20' - **Erich Piovani** (University of Padova, Italy) *'Role of Hedgehog signaling in T-cell acute lymphoblastic leukemia'*

20' - **Neal S. Young** (National Heart, Lung and Blood Institute, NIH, Bethesda, U.S.A.) *'Clonality in Context'*

12:30-14:00 Lunch

14:00- 15:40 **Session 4 - Novel therapeutic targets and strategies** Chairpersons: **Franco Buonaguro** (Istituto Nazionale Tumori, Naples, Italy) and **Donna D'Agostino** (University of Padova, Italy)

20' - **Luca Scorrano** (University of Padova/VIMM, Italy) *'The role of the mitochondria cristae shaping protein Opa1 in lymphoma'*

20' - **Vincenzo Ciminale** (University of Padova/IOV, Italy) *'Mitochondrial reactive oxygen species prime T-ALL cells to apoptosis by engaging the OMA1-OPA1 axis'*

20' - **Ildikò Szabò** (University of Padova, Italy) *'Pharmacological targeting of a mitochondrial ion channel against chronic lymphocytic leukemia'*

20' - **Meike Vogler** (Goethe University Frankfurt, Germany) *'Mitochondrial priming and BH3-mimetics in lymphoid malignancies'*

20' - **Andrea Rasola** (University of Padova, Italy) *'Targeting the metabolic liabilities of B-cell chronic lymphocytic leukemia'*

15:40-16:00 Coffee Break

16:00-17:40 **Session 4 (continued).** Chairpersons: **Gianpiero Semenzato** (University of Padova, Italy) and **Maria Grazia Romanelli** (University of Verona, Italy)

20' - **Carlo Croce** (Ohio State University, Columbus, U.S.A.) *'MicroRNA dysregulation to identify therapeutic targets'*

20' - **Stefano Indraccolo** (IOV, Padova, Italy) *'Histone deacetylase inhibitors and Notch signaling in T acute lymphoblastic leukemia'*

20' - **Giuseppe Basso** (University of Padova, Italy) *'Personalized therapy in resistant childhood ALL'*

20' - **Francesco Piazza** (University of Padova/VIMM, Italy) *'Protein kinases CK1 and CK2 in B cell malignancies'*

20' - **Olivier Hermine** (Hôpital Necker, Paris, France) '*HCV-related B cell lymphoma physiopathology and therapeutic implications*'

19:30 **Social Dinner**

15th European LeukemiaNet Symposium

Wednesday, March 21, 2018

Time

Chairs/Contributors

10:00 - 10:30 Coffee Break

MAIN SESSION – Sala del Portego

10:30 - 12:00 **Keynote lectures and Merit Awards**

R. Hehlmann, L. Chieco-Bianchi

10' Welcome and Introduction

ELN Merit Awards to S. Saußele and U. Berger

R. Hehlmann

20' Minimal residual disease (MRD) in acute myeloid leukemia (AML):
can it already serve as a surrogate for survival?

G. Ossenkoppele

20' The new ELN management recommendations for myeloproliferative
neoplasms (MPN)

G. Barosi

20' CAR-T-cells in hematologic neoplasias

C. Rössig

20' 50 years of chronic myeloid leukemia (CML) research:
where do we stand today?

M. Baccarani

12:00 - 13:00 Lunch

13:00 - 15:00 **Acute myeloid leukemia (AML)/Minimal residual disease (MRD)**

WP5/WP12/WP10 – MRD on the way to surrogacy

G. Ossenkoppele, C. Thiede

24' Introduction for the Munich meeting

G.J. Schuurhuis

24' Next generation sequencing (NGS) for MRD in AML

P. Valk

24' Molecular MRD general overview

C. Thiede

24' Automated analysis of MRD in AML

F. Lacombe/M.C. Bené

24' MRD on the way to surrogacy

R. Walter

15:00 - 15:30

Coffee Break

15:30 - 18:00 **AML/MRD continued (WP5/WP12/WP10)**

24' Discussion on other subtopics with short introductions

G.J. Schuurhuis/M.C. Bené

24' Requirements for multicenter studies

M. Subklewe

24' Peripheral blood MRD

L. Maurillo

24' Timepoints of interest

J. Cloos

24' Leukemia stem cells

G.J. Schuurhuis

Discussants: C. Bloomfield, G.J. Schuurhuis, F. Lacombe, M.C. Bené, W. Kern, M. Subklewe, S. Freeman, J. Cloos, F. Buccisano, C. Thiede, P. Valk, M. Heuser, K. Döhner, B. van de Reijden, R. Walter, R. Hills, A. Venditti, G. Ossenkoppele, P. Vijas, J. Phillipe, R. Dillon, L. Maurillo

Wednesday, March 21, 2018

Time	PARALLEL SESSION – Sala del Giardino	Chairs/Contributors
9:00 - 10:00	ELN Steering Committee Meeting (ELN lead participants only)	
10:00 - 10:30	Coffee Break	
12:00 - 13:00	Lunch	
13:00 - 15:00	Myeloproliferative neoplasia (MPN), WP9 - New projects	J. Kiladjian, T. Barbui
15'	The place of IFN in the management of MPNs and possible new clinical trials	J. Kiladjian
15'	ELN survey on DVT in MPN: background for new anticoagulants	T. Barbui
15'	New anticoagulants for the secondary prevention of venous thrombosis	M. Griesshammer
15'	Collaborative research on <i>JAK2 V617F</i> and <i>KIT D816V</i> cases	A. Reiter
15'	Clinical correlates of triple-negative patients with primary myelofibrosis	A. Vannucchi
15'	MPN Registry Research. Collaborative research potential	M. Björkholm
15'	New research platforms for the exploitation of individualized medicines	G. Barosi
15'	Spanish registry on polycythemia vera, essential thrombocytosis and myelofibrosis: a platform for collaboration	A. Alvarez-Larrán
15:00 - 15:30	Coffee Break	
15:30 - 17:30	Chronic myeloid leukemia (CML), WP4 - The path to cure	M. Baccarani, S. Sauße
15'	EURO-SKI (Stop Kinase Inhibitors) – What next?	S. Sauße
15'	Does the immune system contribute to treatment free remission?	S. Mustjoki
15'	Discussing the ELN recommendations	M. Baccarani
15'	Updating the ELN recommendations for mutational analysis	S. Soverini
15'	The definition of progression in the tyrosine kinase inhibitor (TKI) era	M. Lauseker
15'	New TKIs, ABL001 (Asciminib)	A. Hochhaus
15'	New TKIs, PF-116	A. Turkina
15'	Determinants of survival and center effects in CML	R. Hehlmann

Thursday, March 22, 2018

Time	MAIN SESSION – Sala del Portego	Chairs/Contributors
8:30 - 10:30	HARMONY Update with AML pilot working meeting	J. Hernandez, L. Bullinger
30'	HARMONY 2018 - what has happened so far	J. Hernandez
30'	WP2 - update of the pilot study	L. Bullinger
30'	WP3/4 - HARMONY data platform update	C. van Speybroeck, R. Medina
30'	Update on discussion of outcomes definitions Key Opinion Leaders	R. Hehlmann,
10:30 - 11:00	Coffee Break	
11:00 - 13:00	HARMONY: AML pilot working meeting (WP1, WP2, WP3/4, WP5)	L. Bullinger
120'	Working group meeting with discussion what to do/adjust/etc. - incorporation of first data set - feedback on work-flow - problems? - adjustments needed? - discussion of first data analysis steps	
13:00 - 14:00	General Assembly and summaries of the WP sessions	R. Hehlmann
10'	General Assembly: Report from the steering committee	R. Hehlmann
8'	WP4	M. Baccarani
8'	WP5	G. Ossenkopele
8'	WP6	D. Hoelzer
8'	WP9	T. Barbui
8'	WP14	D. Niederwieser
8'	HARMONY	J. Hernandez
14:00	SMALL FAREWELL LUNCH	

Thursday, March 22, 2018

Time	PARALLEL SESSION – Sala del Giardino	Chairs/Contributors
8:30 - 10:30	Stem cell transplantation (SCT), WP14	D. Niederwieser, J. Apperley
17'	Alternative donor therapy for Thalassemia and SCT in pediatric patients	J. de la Fuente
17'	Multiple myeloma, new projects	G. Gahrton
17'	GvHD overview	T. Ruutu
17'	CAR-T therapy, gene editing	E. Ruggiero
17'	Randomized double blind placebo controlled mesenchymel stem cell (MSC) study for GvHD – Rethrim	D. Niederwieser
17'	HCT vs CT: recruitment termination	D. Niederwieser
17'	Education in SCT	M. Aljurf
10:30 - 11:00	Coffee Break	
11:00 - 13:00	Acute lymphoblastic leukemia (ALL), WP6 - MRD guided treatment	D. Hoelzer, R. Bassan
15'	First analysis of the GIMEMA LAL2116 frontline dasatinib-blinatumomab protocol for Philadelphia chromosome positive (Ph+) ALL patients	R. Foà
15'	First interim analysis (60 patients) of the Ph+ GRAAPH-2014 trial with nilotinib front-line	P. Rousselot
15'	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Ph- ALL (PETHEMA)	J.-M. Ribera
15'	Results of the GRAALL-2005 trial and the principle of the current GRAALL-2014 trial, all for Ph- ALL	H. Dombret
15'	Final report on clinical outcomes by RALL-2009 protocol	E. Parovichnikova
15'	Clofarabine-cyclophosphamide for Relapsed/Refractory ALL (GIMEMA)	R. Bassan
15'	MRD response according to the genetic landscape of Ph-ALL patients enrolled in the GIMEMA LAL1913 protocol	S. Chiaretti
15'	MRD dynamics on non-intensive but non-interruptive treatment	O. Gavrulina
14:00	SMALL FAREWELL LUNCH	